Tirbanibulin

Tirbanibulin
Clinical data
Trade names	Klisyri, Onakta
Other names	KX2-391
AHFS/Drugs.com	Monograph
License data	US DailyMed: Tirbanibulin;
Pregnancy; category	AU: D;
Routes of; administration	Topical
Drug class	Microtubule inhibitor
ATC code	D06BX03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide;
CAS Number	897016-82-9;
PubChem CID	23635314;
DrugBank	DB06137;
ChemSpider	24633341;
UNII	4V9848RS5G;
KEGG	D11691;
ChEBI	CHEBI:231702;
ChEMBL	ChEMBL571546;
PDB ligand	DN0 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID30237862 ;
ECHA InfoCard	100.305.161
Chemical and physical data
Formula	C26H29N3O3
Molar mass	431.536 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1;
	InChI InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30); Key:HUNGUWOZPQBXGX-UHFFFAOYSA-N;

Tirbanibulin, sold under the brand name Klisyri, is a medication used for the treatment of actinic keratosis (AK) on the face or scalp. It functions by inhibiting both tubulin polymerization and Src kinase signaling. It is potentially effective in impeding the development of squamous cell carcinoma in situ.

The most common side effects include local skin reactions, application site pruritus, and application site pain.

Tirbanibulin was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.